HR and breast carcinoma: For patients with hormone receptor positive (HR+)/human epidermal growth factor receptor-2 negative (HER2-) advanced (i.e., metastatic, locally advanced, or stage III or IV) breast cancer, standard treatments include endocrine monotherapy or targeted therapy with an anti-estrogen in patients with non-visceral or asymptomatic visceral tumors [1].